论文部分内容阅读
目的观察紫杉醇脂质体每周给药联合吉西他滨治疗晚期乳腺癌的疗效和不良反应。方法 36例晚期乳腺癌患者,采用紫杉醇脂质体80mg/m2,静滴,第1、8、15天;吉西他滨1g/m2,静滴,第1、8天;21天为1周期。结果 36例均可评价疗效,完全缓解(CR)2例(5.6%),部分缓解(PR)19例(52.8%),稳定(SD)8例(22.2%),进展(PD)7例(19.4%),总有效率(CR+PR)58.3%。中位肿瘤进展时间(TTP)7.8个月。中位生存时间(OS)19.0个月。主要不良反应为骨髓抑制、脱发、周围神经毒性。结论紫杉醇脂质体每周给药联合吉西他滨治疗晚期乳腺癌有效率较高,耐受性良好,值得在临床推广应用。
Objective To observe the efficacy and side effects of weekly administration of paclitaxel liposome combined with gemcitabine in the treatment of advanced breast cancer. Methods Thirty-six patients with advanced breast cancer were treated with paclitaxel liposome 80mg / m2 intravenously for days 1, 8 and 15; gemcitabine 1g / m2 for intravenous infusion for days 1 and 8; and for 21 days for 1 cycle. Results All of the 36 cases were evaluated in 2 cases (5.6%) of complete remission (CR), 19 cases (52.8%) of partial remission (PR), 8 cases (22.2%) of stable (SD) 19.4%), total effective rate (CR + PR) 58.3%. Median tumor progression time (TTP) 7.8 months. Median survival time (OS) 19.0 months. The main adverse reactions were myelosuppression, hair loss and peripheral neurotoxicity. Conclusion paclitaxel liposome weekly combined with gemcitabine in the treatment of advanced breast cancer is more efficient and well tolerated, which is worthy of clinical application.